Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L B Grochow

Showing results (61-70 of 85) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limitingE K Rowinsky, V Chaudhry, A A Forastiere, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancerM J Kennedy, D K Armstrong, A M Huelskamp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion scheduleM A Carducci, J Gilbert, M K Bowling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doubletM J Kennedy, M L Zahurak, R C Donehower, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemiaE K Rowinsky, A Adjei, R C Donehower, et al.
Neurosurgery|November 1, 1982
Improved rabbit brain tumor model amenable to diagnostic radiographic proceduresB S Carson, J H Anderson, S A Grossman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 1998
A phase I and pharmacologic study of DMP 840 administered by 24-hour infusionS O'Reilly, S D Baker, S Sartorius, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 1999
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancerS D Baker, M Wirth, P Statkevich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 1999
Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusionJ P Stevenson, D DeMaria, J Sludden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedulesE K Rowinsky, D A Noe, L B Grochow, et al.
Pageof 9

Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limitingE K Rowinsky, V Chaudhry, A A Forastiere, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancerM J Kennedy, D K Armstrong, A M Huelskamp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion scheduleM A Carducci, J Gilbert, M K Bowling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doubletM J Kennedy, M L Zahurak, R C Donehower, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemiaE K Rowinsky, A Adjei, R C Donehower, et al.
Neurosurgery|November 1, 1982
Improved rabbit brain tumor model amenable to diagnostic radiographic proceduresB S Carson, J H Anderson, S A Grossman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 1998
A phase I and pharmacologic study of DMP 840 administered by 24-hour infusionS O'Reilly, S D Baker, S Sartorius, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 1999
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancerS D Baker, M Wirth, P Statkevich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 1999
Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusionJ P Stevenson, D DeMaria, J Sludden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedulesE K Rowinsky, D A Noe, L B Grochow, et al.
Pageof 9